Ultragenyx Pharmaceutical
| Type | Public |
| HQ | Novato, US |
| Founded | 2010 |
| Size (employees) | 376 (est) |
| Website | ultragenyx.com |
Ultragenyx Pharmaceutical was founded in 2010 and is headquartered in Novato, US
Report incorrect company information
Viewing summary data as a guest
Sign up for free to see all dataKey People/Management at Ultragenyx Pharmaceutical
Emil D. Kakkis
Chief Executive Officer and President
Camille Bedrosian
Chief Medical Officer and Executive Vice President
Wladimir Hogenhuis
COO
Dennis Huang
Chief Technical Operations Officer and Executive Vice President
Thomas Kassberg
Chief Business Officer and Executive Vice President
Karah Parschauer
General Counsel and Executive Vice President
Report incorrect company information
Ultragenyx Pharmaceutical Office Locations
Ultragenyx Pharmaceutical has an office in Novato
Novato, (HQ)
60 Leveroni Ct
Report incorrect company information
Ultragenyx Pharmaceutical Financials and Metrics
Ultragenyx Pharmaceutical Revenue
Ultragenyx Pharmaceutical's revenue was reported to be $2.61 m in FY, 2017
| USD | |
|---|---|
Revenue (Q3, 2018) | 11.8m |
Gross profit (Q3, 2018) | 11.5m |
Gross profit margin (Q3, 2018), % | 97.7% |
Net income (Q3, 2018) | (87.3m) |
EBIT (Q3, 2018) | (89.6m) |
Market capitalization (4-Dec-2018) | 2.6b |
Closing stock price (4-Dec-2018) | 50.4 |
Cash (30-Sep-2018) | 83.0m |
Ultragenyx Pharmaceutical's current market capitalization is $2.6 b.
Annual
Annual
Quarterly
| USD | Q1, 2014 | Q2, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 55.4m | 17.5m | 178.0m | 52.4m | 166.7m | 70.8m | 55.1m | 142.3m | 159.5m | 90.8m | 60.4m | 226.7m | 110.9m | 83.0m |
Accounts Receivable | 3.7m | 17.4m | 9.2m | |||||||||||
Inventories | 2.1m | 3.3m | 5.6m | |||||||||||
Current Assets | 169.6m | 158.2m | 350.5m | 336.5m | 460.7m | 430.2m | 411.1m | 416.8m | 444.7m | 419.8m | 390.9m | 581.6m | 604.7m | 567.5m |
Annual
Quarterly
| USD | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | (21.4m) | (51.2m) | (39.2m) | (52.8m) | (109.7m) | (64.9m) | (68.3m) | (141.2m) | (220.4m) | 30.3m | (22.5m) | (109.8m) | |||
Depreciation and Amortization | 463.0k | 1.2m | 1.2m | 2.2m | 3.3m | 6.2m | 12.2m | 16.6m | |||||||
Accounts Payable | 3.5m | 3.6m | 4.2m | 5.8m | 4.8m | 4.4m | 6.0m | 2.8m | 6.6m | 3.0m | 6.4m | 3.9m | (1.3m) | 1.4m | (593.0k) |
Cash From Operating Activities | (34.9m) | (84.5m) | (61.2m) | (110.0m) | (172.0m) | (89.5m) | (165.6m) | (234.7m) |
| USD | Y, 2018 |
|---|---|
Financial Leverage | 1.2 x |
Report incorrect company information
Ultragenyx Pharmaceutical News and Updates
Report incorrect company information
Ultragenyx Pharmaceutical Blogs
September 26, 2018
Ultragenyx to Present at Jefferies Gene Therapy Summit
Ultragenyx to Present at Jefferies Gene Therapy Summit
Content Import
Wed, 09/26/2018 - 08:34
Ultragenyx to Present at Jefferies Gene Therapy Summit
Sep 26, 2018
This release is a backfill from a News Wire
General
NOVATO, Calif., Sep…
September 17, 2018
Ultragenyx Expands Leadership Team and Appoints Dr. Wladimir Hogenhuis as Chief Operating Officer
Ultragenyx Expands Leadership Team and Appoints Dr. Wladimir Hogenhuis as Chief Operating Officer
Content Import
Mon, 09/17/2018 - 08:33
Ultragenyx Expands Leadership Team and Appoints Dr. Wladimir Hogenhuis as Chief Operating Officer
Sep 17, 2018
This releas…
August 02, 2018
Ultragenyx Reports Second Quarter 2018 Financial Results and Corporate Update
NOVATO, Calif , Aug. 02, 2018 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today reported its financial results and corporate update for the quarter ended June 30, 2018 .
July 27, 2018
Ultragenyx to Host Conference Call for Second Quarter 2018 Financial Results and Corporate Update
NOVATO, Calif. , July 27, 2018 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that it will host a conference call on Thursday, August 2, 2018 at 5pm ET to
July 26, 2018
Ultragenyx Announces First Patient Dosed in Phase 1/2 study of DTX401, a Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa); FDA Grants Fast Track Designation to Gene Therapy Program
NOVATO, Calif. , July 26, 2018 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that the first patient has been dosed in the Phase 1/2 study of DTX401, an
Ultragenyx Pharmaceutical Company Life and Culture
Report incorrect company information
Ultragenyx Pharmaceutical Frequently Asked Questions
When was Ultragenyx Pharmaceutical founded?
Ultragenyx Pharmaceutical was founded in 2010.
Who are Ultragenyx Pharmaceutical key executives?
Ultragenyx Pharmaceutical's key executives are Emil D. Kakkis, Camille Bedrosian and Wladimir Hogenhuis.
How many employees does Ultragenyx Pharmaceutical have?
Ultragenyx Pharmaceutical has 376 employees.
What is Ultragenyx Pharmaceutical revenue?
Latest Ultragenyx Pharmaceutical annual revenue is $2.6 m.
What is Ultragenyx Pharmaceutical revenue per employee?
Latest Ultragenyx Pharmaceutical revenue per employee is $6.9 k.
Who are Ultragenyx Pharmaceutical competitors?
Competitors of Ultragenyx Pharmaceutical include Nightstar Therapeutics, Aevi Genomic Medicine and Illumina.
Where is Ultragenyx Pharmaceutical headquarters?
Ultragenyx Pharmaceutical headquarters is located at 60 Leveroni Ct, Novato.
Where are Ultragenyx Pharmaceutical offices?
Ultragenyx Pharmaceutical has an office in Novato.
How many offices does Ultragenyx Pharmaceutical have?
Ultragenyx Pharmaceutical has 1 office.